Back to search

McMaster University

Metabolomic Studies of Temozolomide Response in Patient-Derived Models of Glioblastoma

Abstract

dc:description.abstract

Glioblastoma (GBM) is an aggressive primary brain tumour for which temozolomide (TMZ) remains a core component of first-line therapy as the only systemic drug with an established survival benefit in this setting. However, over half of patients exhibit intrinsic or acquired resistance and clinical tools remain limited for non-invasive and dynamic therapeutic response assessment. This thesis investigated whether untargeted metabolomic analyses can identify circulating biomarkers that differentiate TMZ responsiveness before or at early stages of treatment remote from the tumour site in patient-derived models of GBM. Serum samples were collected at pre-engraftment, pre-treatment, and post-treatment timepoints from mice bearing TMZ-resistant (BT935) or TMZ-sensitive (MBT06) patient-derived xenografts following 2 and 5 days of TMZ exposure. The two corresponding tumour lines were also analyzed in vitro using cell extracts and conditioned media, representing intracellular and extracellular compartments, respectively. A metabolomic data workflow was developed using capillary electrophoresis-mass spectrometry and reversed-phase liquid chromatography-mass spectrometry to characterize polar metabolites and lipids from three biospecimen types with stringent quality control. Overall, twelve serum metabolites were identified as biomarker candidates of TMZ resistance in this pilot study. Histidine, ornithine, glycine betaine, and choline were significantly higher in TMZ-resistant than TMZ-sensitive serum before TMZ administration. During treatment, broad coordinated depletion extended across the resistant serum metabolome, including the endogenous candidate panel; by day 5, all 11 endogenous candidates were significantly lower in resistant than sensitive serum. Corresponding cell extract profiles showed broadly opposing treatment-associated directionality, including higher median abundance in the resistant model for most primary candidates. The TMZ-derived drug metabolite, 5-aminoimidazole-4-carboxamide (AIC), was detected only following TMZ exposure and showed compartment-dependent correlations with both the candidate panel and broader metabolic response. Correlation analyses, compartment-specific AIC relationships, state-aligned multiblock integration, and metabolic pathway analysis provided deeper biochemical context linking systemic and tumour metabolic phenotypes. These findings establish a pre-clinical biomarker panel requiring further validation in GBM patients, which may allow for early detection of TMZ resistance for more informed clinical decision-making and improved overall survival.

Degree

thesis:*
Department dc:contributor.department
Chemical Biology
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zachary E. Kazaz
Advisor dc:contributor.advisor
  • Philip, Britz-McKibbin

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
McMaster University
Base URL
macsphere.mcmaster.ca/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Zachary E. Kazaz. Metabolomic Studies of Temozolomide Response in Patient-Derived Models of Glioblastoma. 2026. https://hdl.handle.net/11375/33765